$0.919
-0.062 (-6.72%)收盘时
ESLA 同业对比
In the context of the broader market, ESLA competes directly with industry leaders such as BCTX and ZYBT. With a market capitalization of $42.85M, it holds a leading position in the sector. When comparing efficiency, ESLA's gross margin of N/A stands against BCTX's N/A and ZYBT's 20.51%. Such benchmarking helps identify whether Estrella Immunopharma Inc is trading at a premium or discount relative to its financial performance.
Estrella Immunopharma Inc 财务表现
The company has reported consistent net losses, with a net income of -5,544,878 USD in Q2 2025 and a current ratio of only 0.20, indicating liquidity issues.
Financials
FY2026Q2
0.00
Total Revenue
FY2026Q2
YoY:
-62.41%
-2.08M
Operating Profit
FY2026Q2
YoY:
-58.41%
-2.31M
Net Income after Tax
FY2026Q2
YoY:
-66.67%
-0.05
EPS - Diluted
FY2026Q2
YoY:
+329.22%
-1.78M
Free Cash Flow
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。